Business Wire

HISENSE

1.6.2021 12:00:08 CEST | Business Wire | Press release

Share
Building Sustainable Future: Hisense and Employees

Living under the new-normal, ESG has become one of the world's most trending topics. A positive impact on society and providing sustainable development opportunities for employees have gradually become the new criteria for companies to represent their growth. By putting talent first, Hisense strives to build a global team that includes people from different cultures and unique experiences, and to provide an equal and healthy working environment to drive its success. Together with over 90,000 employees around the world, Hisense is creating a sustainable future and exerting positive social influence constantly.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005474/en/

Focusing on local talent cultivation and cultural inclusion

Hisense supports local communities to relieve their unemployment pressure and to reduce the indirectly related crime rate. Through its investment in industrial parks worldwide, Hisense creates more than 3,000 job positions in South Africa and over 2,000 in Mexico with an expectation to expand to over 7,000 in the future, which successfully helps the local region expand its economy and boost sustainable development.

Hisense provides equal employment opportunities regardless of race and gender with professional and systematic training when recruiting local employees. For example, Nicalette, a single mother, who joined Hisense South Africa in 2002, was promoted to After-sales Manager through her excellent work performance and rapidly growing ability. Hisense’s talent employment and cultivation system has increased her passion for work and also made her life improved, according to Nicalette.

Caring for employees' career development

To empower employees, Hisense has created the necessary conditions and space for them to maximize their potential and value. Hisense implements a flexible promotion mechanism, allowing employees to choose between career paths of “management” and “R&D” for further development, which ensures a smooth promotion channel for everyone.

Hisense College, the corporate university, aims to help employees achieve better career development. A comprehensive training structure and multiple internal training platforms (including offline lecture, website, APP, etc.) are in place to help employees learn and improve anytime, anywhere.

"What makes working here different from other companies is that Hisense always motivates its employees to accomplish career goals and gives them great supports, allowing them to grow with the company." said Robin Silberbauer, who joined Hisense South Africa in 2015.

Caring for employees' health and wellbeing

During the pandemic, Hisense spares no efforts to assure employees' and their families' health through distributing epidemic prevention materials and supporting working at home.

Hisense also joins hands with professional EAP (“Employee Assistance Program”) organizations to provide mental health care for employees and their families, so that each employee can easily obtain professional psychological counselling services, which efficiently help them improve mental health and take up challenges of work and life.

Hisense will focus on talent development in the long term and actively create an inclusive workplace environment to advance the sustainable development of local communities with its global workforce.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release

The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye